Business Description
Ocumension Therapeutics
ISIN : KYG674111011
Share Class Description:
FRA:5DG: Ordinary SharesCompare
Compare
Traded in other countries / regions
01477.Hong Kong5DG.Germany IPO Date
2020-07-15Description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 63.43 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.9 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 101.1 | |||||
| 3-Year EBITDA Growth Rate | 60.6 | |||||
| 3-Year EPS without NRI Growth Rate | 57.3 | |||||
| 3-Year FCF Growth Rate | 23.5 | |||||
| 3-Year Book Growth Rate | -1.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 73.82 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 97.01 | |||||
| 9-Day RSI | 86.42 | |||||
| 14-Day RSI | 74.52 | |||||
| 6-1 Month Momentum % | -5.3 | |||||
| 12-1 Month Momentum % | -30.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.35 | |||||
| Quick Ratio | 5 | |||||
| Cash Ratio | 4.33 | |||||
| Days Inventory | 131.71 | |||||
| Days Sales Outstanding | 137.43 | |||||
| Days Payable | 93.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -1.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.28 | |||||
| Operating Margin % | -108.97 | |||||
| Net Margin % | -104.12 | |||||
| FCF Margin % | -150.4 | |||||
| ROE % | -11.45 | |||||
| ROA % | -10.39 | |||||
| ROIC % | -16.66 | |||||
| 3-Year ROIIC % | 7.27 | |||||
| ROC (Joel Greenblatt) % | -68.29 | |||||
| ROCE % | -11.2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.05 | |||||
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 2.78 | |||||
| EV-to-EBIT | -9.05 | |||||
| EV-to-EBITDA | -11.31 | |||||
| EV-to-Revenue | 9.34 | |||||
| EV-to-FCF | -5.37 | |||||
| Price-to-Net-Current-Asset-Value | 4.69 | |||||
| Price-to-Net-Cash | 6.25 | |||||
| Earnings Yield (Greenblatt) % | -11.05 | |||||
| FCF Yield % | -12.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ocumension Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 39.788 | ||
| EPS (TTM) (€) | -0.064 | ||
| Beta | 0.47 | ||
| Volatility % | 49.44 | ||
| 14-Day RSI | 74.52 | ||
| 14-Day ATR (€) | 0.026862 | ||
| 20-Day SMA (€) | 0.5361 | ||
| 12-1 Month Momentum % | -30.56 | ||
| 52-Week Range (€) | 0.466 - 0.935 | ||
| Shares Outstanding (Mil) | 666.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ocumension Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ocumension Therapeutics Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ocumension Therapeutics Frequently Asked Questions
What is Ocumension Therapeutics(FRA:5DG)'s stock price today?
The current price of FRA:5DG is €0.75. The 52 week high of FRA:5DG is €0.94 and 52 week low is €0.47.
When is next earnings date of Ocumension Therapeutics(FRA:5DG)?
The next earnings date of Ocumension Therapeutics(FRA:5DG) is .
Does Ocumension Therapeutics(FRA:5DG) pay dividends? If so, how much?
Ocumension Therapeutics(FRA:5DG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers